Savers Value Village CEO Mark Walsh Exercises Options, Sells Shares

What Happened

• Mark T. Walsh, CEO and Director of Savers Value Village, exercised stock options and sold the resulting shares. On Aug 10, 2026 he exercised 100,000 options (50,000 @ $1.41; 50,000 @ $3.16) and sold 100,000 shares in the open market at a weighted average price of $12.20 (proceeds reported $1,220,360). On Aug 11, 2026 he exercised another 92,059 options (42,059 @ $1.41; 50,000 @ $3.16) and sold 92,059 shares at a weighted average price of $11.93 (proceeds reported $1,097,905).
• Total exercised = 192,059 shares; total exercise cost (cash paid) ≈ $445,803; total reported sale proceeds ≈ $2,318,265. These transactions resulted in an approximate net cash difference (proceeds minus exercise cost) of about $1.87M.

Key Details

• Transaction dates: Aug 10–11, 2026. Filing date: Aug 12, 2026 (filed within the typical 2‑business‑day Form 4 window).
• Sale prices and ranges:
  • Aug 10 sale weighted avg: $12.20 (execution range $11.74–$12.41) — F2.
  • Aug 11 sale weighted avg: $11.93 (execution range $11.72–$12.15) — F3.
• All sales were made pursuant to a 10b5‑1 trading plan adopted by Mr. Walsh on March 17, 2026 — F1.
• Derivative/option details: options were granted under the 2019 Management Incentive Plan (some grants from Oct 7, 2019 and Dec 9, 2020; vesting details noted in F4–F7). Some grants were fully vested by 2024–2025 per the footnotes.
• Shares owned after the transactions are not provided here; check the full Form 4 for reported beneficial ownership counts.

Context

• These filings show an exercise of options (derivative code M) followed by open‑market sales (code S). Because the sales were executed under a prearranged 10b5‑1 plan, they are typically routine plan‑driven transactions rather than ad‑hoc sales.
• When an insider exercises options and immediately sells the shares, it’s effectively a way to realize gains rather than a clear signal of long‑term sentiment. The facts here are: options exercised (cash paid for exercise) and shares sold in the market under a 10b5‑1 plan.
• For full detail (exact remaining holdings, strike details per grant, or breakdown of shares sold at each execution price), refer to the complete Form 4 (Accession 0001977188-26-000008) or request the SEC staff disclosure referenced in the footnotes.